HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $5 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 91.5%

Neg 0% Neu 91.5% Pos 0%

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and maintains $5 price target.